Related Experiment Video
Updated: Oct 18, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.6K
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
1Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
Pharmacology & Therapeutics
|September 28, 2021
Summary
Chimeric antigen receptor (CAR) T cell therapy shows promise for treating multiple myeloma, offering improved outcomes. Research explores new targets and strategies to overcome resistance and enhance CAR T cell therapy efficacy.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Multiple myeloma remains an incurable malignancy despite recent treatment advancements.
- Emerging immunotherapies, including chimeric antigen receptor (CAR) T cell therapy, offer new treatment avenues.
Purpose of the Study:
- To review the clinical efficacy and safety of current multiple myeloma CAR T cell therapies.
- To explore potential resistance mechanisms and novel strategies to enhance CAR T cell therapy.
Main Methods:
- Comprehensive review of existing clinical data on multiple myeloma CAR T cell therapies.
- Analysis of B Cell Maturation Antigen (BCMA) as a primary target and exploration of other targets for single or dual-target CAR T approaches.
Main Results:
- The first CAR T cell therapy for multiple myeloma targeting BCMA received FDA approval in March 2021.
- Significant response rates and clinical efficacy observed in heavily pretreated patients.
Conclusions:
- CAR T cell therapy represents a significant advancement in multiple myeloma treatment.
- Ongoing research focuses on overcoming resistance mechanisms like CAR T cell clearance, antigenic escape, and immunosuppressive microenvironments.
- Future directions include exploring novel targets and combination strategies to improve long-term outcomes.
